Breaking Finance News

A statement released earlier today by Maxim Group about CASI Pharmaceuticals Inc (NASDAQ:CASI) raises the target price to $4.00

Having a price of $1.05, CASI Pharmaceuticals Inc (NASDAQ:CASI) traded 5.31% higher on the day. With the last close down 1.01% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CASI has recorded a 50-day average of $1.12 and a two hundred day average of $1.18. Trading volume was up over the average, with 91,365 shares of CASI changing hands over the typical 50,877

In a report issued Wednesday September 21, 2016 Maxim Group raised the target price of CASI Pharmaceuticals Inc (NASDAQ:CASI) to $4.00 reporting a possible upside of 2.81%.

On Tuesday June 23, 2015, H.C. Wainwright released a statement on CASI Pharmaceuticals Inc (NASDAQ:CASI) upped the target price from $0.00 to $2.00 that suggested an upside of 0.20%.

See Chart Below

CASI Pharmaceuticals Inc (NASDAQ:CASI)

CASI Pharmaceuticals Inc has a one year low of $0.58 and a one year high of $1.82 CASI’s total market value is presently $0.

Brief Synopsis About CASI Pharmaceuticals Inc (NASDAQ:CASI)

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *